PA8847901A1 - Combinación farmacéutica sinérgica que comprende un antagonista del receptor de estrógeno y una progestina - Google Patents

Combinación farmacéutica sinérgica que comprende un antagonista del receptor de estrógeno y una progestina

Info

Publication number
PA8847901A1
PA8847901A1 PA20098847901A PA8847901A PA8847901A1 PA 8847901 A1 PA8847901 A1 PA 8847901A1 PA 20098847901 A PA20098847901 A PA 20098847901A PA 8847901 A PA8847901 A PA 8847901A PA 8847901 A1 PA8847901 A1 PA 8847901A1
Authority
PA
Panama
Prior art keywords
progestine
antigonist
pharmaceutical combination
receiver
estrogen
Prior art date
Application number
PA20098847901A
Other languages
English (en)
Inventor
Wintermantel Tim
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PA8847901A1 publication Critical patent/PA8847901A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

COADMINISTRACIÓN DE UN ANTAGONISTA DEL RECEPTOR DE ESTRÓGENO Y UNA PROGESTINA PARA TRATAR ENFERMEDADES GINECOLÓGICAS QUE SON EL RESULTADO DEL CRECIMIENTO ANORMAL DEL TEJIDO DEL ÚTERO, TALES COMO LA ENDOMETRIOSIS O LOS FIBROIDES UTERINOS.
PA20098847901A 2008-11-11 2009-11-09 Combinación farmacéutica sinérgica que comprende un antagonista del receptor de estrógeno y una progestina PA8847901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102008057230A DE102008057230A1 (de) 2008-11-11 2008-11-11 Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin

Publications (1)

Publication Number Publication Date
PA8847901A1 true PA8847901A1 (es) 2010-06-28

Family

ID=41606625

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098847901A PA8847901A1 (es) 2008-11-11 2009-11-09 Combinación farmacéutica sinérgica que comprende un antagonista del receptor de estrógeno y una progestina

Country Status (6)

Country Link
AR (1) AR074297A1 (es)
DE (1) DE102008057230A1 (es)
PA (1) PA8847901A1 (es)
TW (1) TW201022251A (es)
UY (1) UY32235A (es)
WO (1) WO2010054758A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481294A (zh) * 2009-09-11 2012-05-30 拜耳医药股份有限公司 作为抗癌药物的取代(杂芳基甲基)乙内酰硫脲
WO2013131105A1 (en) * 2012-03-02 2013-09-06 Sri International Synergistic anti-proliferation activity of tas-108 with mtor inhibitors against cancer cells
WO2016004166A1 (en) * 2014-07-02 2016-01-07 Xavier University Of Louisiana Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
CN104370796B (zh) * 2014-11-21 2016-09-14 扬子江药业集团有限公司 一种醋酸巴多昔芬多晶型b的制备方法
KR20180059427A (ko) 2015-07-14 2018-06-04 노벨파마 컴퍼니 리미티드 에스트로겐 수용체 α 저해 작용을 갖는 에스트로겐 수용체 β 부분 아고니스트 및 이를 사용한 부인과 질환 치료제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
UA68365C2 (en) * 1997-11-06 2004-08-16 Wyeth Corp Peroral contraception by combination of anti-estrogen and progestin
US6265393B1 (en) 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
DE60005693T2 (de) * 1999-07-29 2004-07-29 Eli Lilly And Co., Indianapolis Eine kristalline form von 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophen-hydrochlorid
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
WO2003063859A1 (en) * 2002-01-14 2003-08-07 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
TW200307553A (en) * 2002-05-24 2003-12-16 Akzo Nobel Nv Treatment of post-menopausal complaints in breast cancer patients
JP4656939B2 (ja) 2002-07-22 2011-03-23 イーライ リリー アンド カンパニー フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター
US20080021003A1 (en) * 2006-06-13 2008-01-24 Vladimir Hanes Extended step-down estrogen regimen

Also Published As

Publication number Publication date
TW201022251A (en) 2010-06-16
UY32235A (es) 2010-06-30
WO2010054758A1 (en) 2010-05-20
AR074297A1 (es) 2011-01-05
DE102008057230A1 (de) 2010-05-12

Similar Documents

Publication Publication Date Title
UY32819A (es) Composiciones farmaceuticas de uso oftalmico de antagonistas del receptor dp2
CR20110455A (es) Derivados de indol como antagonistas del receptor crth2
UY35177A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
ECSP12012270A (es) Compuestos de pirazol como inhibidores del receptor sigma
GT201500233A (es) Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
GT201600056A (es) Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih
GT201200147A (es) Antagonistas de espiro-oxindol de mdm2
GT201300122A (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
ECSP15007420A (es) Métodos y composiciones para determinar la resistencia a la terapia con receptor de andrógeno
UY30829A1 (es) Compuestos agonistas y antagonistas del receptor de esfinfosina-1-fosfato
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
GT201400187A (es) Derivados macrocíclicos para el tratamiento de enfermedades
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
DOP2013000043A (es) Composiciones y métodos para inhibir la unión de células madre y células progenitoras a tejido linfoide y para regenerar centros germinales en tejidos linfáticos
HN2012000137A (es) Derivados de 17 - hidroxi - 17 - pentafluoroetil - estra - 4, 9(10) - dien - 11 - arilo, procedimientos para su preparacion y su uso para el tratamiento de enfermedades
PA8847901A1 (es) Combinación farmacéutica sinérgica que comprende un antagonista del receptor de estrógeno y una progestina
CO6420342A2 (es) Derivados de pirazol usados como antagonistas del receptor ccr4
CU20120175A7 (es) Compuestos derivados de 6,7-dihidro-5h-benzo[7]anulenos
CR20140257A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
CL2016002240A1 (es) Derivados de piperidina como antagonista de receptores de orexina
UY32520A (es) Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
AR075260A1 (es) Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
EA201590049A1 (ru) Композиции и способы для лечения участков отсутствующей костной ткани и открытых переломов
MY172937A (en) A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder